Water-soluble PDE4 inhibitors for the treatment of dry eye.
Govek, S.P., Oshiro, G., Anzola, J.V., Beauregard, C., Chen, J., Coyle, A.R., Gamache, D.A., Hellberg, M.R., Hsien, J.N., Lerch, J.M., Liao, J.C., Malecha, J.W., Staszewski, L.M., Thomas, D.J., Yanni, J.M., Noble, S.A., Shiau, A.K.(2010) Bioorg Med Chem Lett 20: 2928-2932
- PubMed: 20378348 
- DOI: https://doi.org/10.1016/j.bmcl.2010.03.023
- Primary Citation of Related Structures:  
3LY2 - PubMed Abstract: 
PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, which is effective in a rabbit model of dry eye and a tear secretion test in rats.
Organizational Affiliation: 
Kalypsys, Inc., 10420 Wateridge Circle, San Diego, CA 92121, United States. sgovek@san.rr.com